U.S., Dec. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07283796) titled 'Phase I Study of HSK47977 Tablets in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma' on Dec. 02.
Brief Summary: This is a Phase I Clinical Study to Evaluate the Safety, Efficacy, and PK/PD Characteristics of HSK47977 Tablets in Subjects with Relapsed or Refractory Non-Hodgkin's Lymphoma.This study includes a Phase Ia dose-escalation stage and a Phase Ib dose-expansion stage, and it is expected to take approximately 2 years.
Study Start Date: Aug. 28
Study Type: INTERVENTIONAL
Condition:
NHL
Intervention:
DRUG: HSK47977
Taken orally once daily.
Recruitment Status: RECRUITING
Sponsor: Haisco Pharmaceutical Group ...